07:17 AM EST, 02/26/2026 (MT Newswires) -- Kymera Therapeutics ( KYMR ) reported a Q4 net loss Thursday of $0.97 per diluted share, compared with a loss of $0.88 a year earlier.

Analysts polled by FactSet expected a loss of $0.78.

Collaboration revenue for the quarter ended Dec. 31 was $2.8 million, compared with $7.4 million a year earlier.

Analysts surveyed by FactSet expected $15 million.

As of Dec. 31, Kymera Therapeutics ( KYMR ) said it had $1.6 billion in cash, cash equivalents and investments, which it expects to provide it with a cash runway into 2029.